講演・口頭発表等 - 山内　慎一

21. Yamauchi S, Loupakis F, Matsusaka S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Stremitzer S, Sebio A, El-Khoueiry RE, Pasquini G, Marmorino F, Schirripa M, Fujimoto Y, Ueno M, Mizunuma N, Lenz HJ.. Association of single nucleotide polymorphisms in genes involved in autophagy with overall survival in patients with metastatic colorectal cancer.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

22. Siamak S, Sunakawa Y, Loupakis F, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry RE, Antoniotti C, Rossini D, Cremolini C, Falcone A, Lenz HJ.. CCL2 polymorphism as a predictive marker for bevacizumab (Bev) in combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts).. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

23. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry RE, Stift J, Wrba F, Gruenberger T, Lenz HJ.. Influence of genetic variations of the angiopoietin and pericyte pathways in resected colorectal liver metastases.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

24. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry RE, Stift J, Wrba F, Gruenberger T, Lenz HJ.. Association outcome with genes involved in immune response and checkpoints in patients with resected colorectal liver metastases.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

25. Hanna DL, Sebio A, Zhang W, Yang D, Loupakis F, Stintzing S, Stremitzer S, Ning Y, Sunakawa Y, Yamauchi S, Matsusaka S, Cremolini C, El-Khoueiry RE, Falcone A, Lenz HJ.. Common genetic variants in genes involved in the Hippo pathway: Novel biomarkers in metastatic colorectal cancer patients treated with irinotecan plus cetuximab.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

26. Sunakawa Y, Volz NB, Zhang W, Yang D, Wakatsuki T, Ning Y, Stintzing S, Stremitzer S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry RE, Iqbal S, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ.. Genetic variants in tumor immune checkpoints as prognostic markers in patients (pts) with localized advanced gastric cancer (AGC).. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

27. Sebio A, Marmorino F, Gerger A, Zhang W, Yang D, Ning Y, Stintzing S, Stremitzer S, Sunakawa Y, Yamauchi S, Matsusaka S, Salvatore L, Cremolini C, El-Khoueiry RE, Falcone A, Lenz HJ.. Genetic variant in the down syndrome candidate region 1 (DSCR1) gene: A novel biomarker in metastatic colorectal cancer.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

28. Stintzing S, Stremitzer S, Heinemann V, Falcone A, Loupakis F, Cremolini C, Antoniotti C, Sunakawa Y, Matsusaka S, Yamauchi S, Zhang W, Yang D, Ning Y, Sebio A, Hanna DL, Siamak S, Lenz HJ.. Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

29. Preusser M, Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, El-Khoueiry RE, Birner P, Lenz HJ.. Influence of genetic variants of genes potentially associated with brain metastases on overall survival in 70 colorectal cancer patients.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

30. Ning Y, Stintzing S, Heinemann V, Zhang W, Yang D, Sunakawa Y, Stremitzer S, Sebio A, Yamauchi S, Matsusaka S, El-khoueiry RE, Barzi A, El-Khoueiry AB, Lenz HJ.. Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical outcome in FIRE-3 trial: A validation study.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

31. Sunakawa Y, Zhang W, Yang D, Wakatsuki T, Ning Y, Stintzing S, Stremitzer S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry RE, Iqbal S, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ.. Association of polymorphisms in the CCL2/CCR2 axis with clinical outcome in localized advanced gastric cancer (AGC) patients (pts) from the United States and Japan.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

32. Zhang W, Schumacher F, Loupakis F, van Den Berg D, Cremolini C, Stintzing S, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, El-khoueiry RE, Falcone A, Lenz HJ.. High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial; NCT00719797).. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

33. Matsusaka S, Loupakis F, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Yamauchi S, Stremitzer S, Sebio A, El-Khoueiry RE, Pasquini G, Marmorino F, Schirripa M, Inoshita N, Ishikawa Y, Ueno M, Mizunuma N, Lenz HJ.. Association of the prognostic role of CXCR4/CXCL12 polymorphism with treatment outcomes after bevacizumab-based chemotherapy in metastatic colorectal cancer.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

34. Ning Y, Zhang W, Yang D, Stintzing S, Sunakawa Y, Stremitzer S, Sebio A, Yamauchi S, Matsusaka S, Zoratto F, Loupakis F, El-Khoueiry RE, Barzi A, El-Khoueiry AB, Kahn M, Lenz HJ.. Genetic variants of CBP and SOX9 to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (FOLFIRI/BEV).. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

35. Sebastian Stintzing, Stefan Stremitzer, Volker Heinemann, Andreas Jung, Yu Sunakawa, Satoshi Matsusaka, Shinichi Yamauchi, Wu Zhang, Dongyun Yang, Yan Ning, Ana Sebio, Diana L. Hanna, Saadat Siamak, Heinz-Josef Lenz. Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

36. Sebio A, Zhang W, Yang D, Stremitzer S, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry RE, Barzi A, Iqbal S, El-Khoueiry AB, Lenz HJ.. Germline polymorphisms in genes involved in the Hippo pathway to predict recurrence in locally advanced colon cancer.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

37. Yang D, Stremitzer S, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry RE, Stift J, Wrba F,Gruenberger T, Lenz HJ.. Association of outcome with genes involved in tumor dormancy in patients with resected colorectal liver metastases.. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 2014.06 Chicago (USA)

38. 花岡まりえ、朝野紗稀子、柴野潤、貫井聖人、原田紡、山本祥馬、杉下哲夫、髙岡亜弓、山本雄大、山内慎一、藤原尚志、賀川弘康、吉原浩之、五十嵐中、徳永正則、絹笠祐介. 大規模データベースに基づく直腸癌に対するロボット支援下手術の短期・長期成績の検討. 第102回大腸癌研究会学術集会 2025.01.31 別府

39. 朝野紗稀子、花岡まりえ、柴野潤、貫井聖人、原田紡、山本祥馬、杉下哲夫、髙岡亜弓、山本雄大、山内慎一、藤原尚志、賀川弘康、徳永正則、絹笠祐介. 当科での直腸癌に対するロボット支援手術後排尿障害リスク因子に関する検討. 第102回大腸癌研究会学術集会 2025.01.31 別府

40. 花岡まりえ、杉下哲夫、柴野潤、杉浦光太、竹中雄輝、徳橋愛彦、鳴海絢、貫井聖人、原田紡、山本祥馬、山本雄大、髙岡亜弓、佐々木恵、山内慎一、絹笠祐介. 当科における原発性直腸癌に対するロボット支援手術と従来式腹腔鏡手術の比較ー短期・長期および教育的側面ー. 第79回日本大腸肛門病学会学術集会 2024.11.30 横浜